MedTrace Logo

Study to Assess the Pharmacokinetics of CT1812 in Older Healthy Volunteers

NCT05248672 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2023-04-12

No results posted yet for this study

Summary

This an open label study to assess the pharmacokinetics of CT1812 in normal healthy volunteers.

Conditions

  • Alzheimer Disease

Interventions

DRUG

CT1812

Study Drug

Sponsors & Collaborators

  • Cognition Therapeutics

    lead INDUSTRY

Principal Investigators

  • Anthony Caggiano, MD · Cognition Therapeutics

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-02-15
Primary Completion
2022-06-01
Completion
2022-06-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05248672 on ClinicalTrials.gov